Are COVID-19 vaccines really safe? Why nobody talks about side effects: US virologist｜Part. 1

Dr. Hakim Djaballah is an Algerian-born American molecular pharmacologist and technologist with expertise in virology and oncology. Dr. Djaballah is a thought leader on drug discovery and development and sits on several advisory boards. He is the co-founder, president and CEO of Keren Therapeutics, a startup company dedicated to the science of aging. Formerly, Dr. Djaballah was the CEO of the Pasteur Institute in Korea, a transnational research institute with a focus on infectious diseases and oncology. Prior to his move to South Korea, Dr. Djaballah was affiliated with the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, USA. MSKCC is the oldest cancer treatment and research institution, founded in 1884. Dr. Djaballah holds a BSc degree from the University of Birmingham (England) and a doctorate degree from the University of Leicester (England).